New cancer drug targets genetic weakness in advanced tumors

NCT ID NCT06130553

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a new drug called AZD3470 in people with advanced solid tumors that have a specific genetic flaw called MTAP deficiency. The main goals are to find a safe dose and see if the drug, given alone or with other cancer treatments, can help control the cancer. It is for adults whose cancer has worsened despite standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS THAT ARE MTAP DEFICIENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

San Francisco, California, 94143, United States
Research Site
WITHDRAWN

West Hollywood, California, 90048, United States
Research Site
RECRUITING

New Haven, Connecticut, 06510, United States
Research Site
RECRUITING

Baltimore, Maryland, 21231, United States
Research Site
RECRUITING

Portland, Oregon, 97239, United States
Research Site
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Research Site
RECRUITING

Providence, Rhode Island, 02903, United States
Research Site
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
RECRUITING

Beijing, 100142, China
Research Site
RECRUITING

Chengdu, 610041, China
Research Site
RECRUITING

Shanghai, 200433, China
Research Site
NOT_YET_RECRUITING

Villejuif, 94805, France
Research Site
RECRUITING

Chūōku, 104-0045, Japan
Research Site
RECRUITING

Kashiwa, 227-8577, Japan
Research Site
RECRUITING

Amsterdam, 1066CX, Netherlands
Research Site
RECRUITING

Seoul, 03080, South Korea
Research Site
RECRUITING

Seoul, 06351, South Korea
Research Site
RECRUITING

Barcelona, 8035, Spain
Research Site
RECRUITING

Madrid, 28027, Spain

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMORS THAT ARE MTAP DEFICIENT